Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

James O. Armitage, Fred R. Dick, Charles E. Platz, Michael P. Corder, Joseph T. Leimert

Research output: Contribution to journalArticle

31 Scopus citations


Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p < 0.001), and to that of those with large cleaved cells (p < 0.05) and large cleaved and large noncleaved cells (p < 0.025). All the patients with large noncleaved cells are alive and "off" therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.

Original languageEnglish (US)
Pages (from-to)929-934
Number of pages6
JournalThe American journal of medicine
Issue number6
Publication statusPublished - Dec 1979


ASJC Scopus subject areas

  • Medicine(all)

Cite this